LPCN 2401
Obesity Management
Key Facts
About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oral therapeutics for metabolic and endocrine disorders. Its core strategy leverages a proprietary solubilization technology (Lip'ral) to reposition established drug molecules with poor water solubility into convenient oral formulations, thereby improving patient compliance. Key achievements include the FDA approval of its oral testosterone replacement therapy, TLANDO®, and the advancement of a diversified pipeline targeting high-need areas like NASH and postpartum depression through the efficient 505(b)(2) regulatory pathway. The company's mission is to enhance health outcomes by overcoming the challenge of oral drug absorption for hydrophobic compounds.
View full company profileTherapeutic Areas
Other Obesity Management Drugs
| Drug | Company | Phase |
|---|---|---|
| Novo Nordisk Collaboration Program | Metaphore Biotechnologies | Discovery |